BROOKS LABORATORIES LTD.

Brooks Laboratories Ltd announced that its Board of Directors, in a meeting held on August 13, 2026, considered and approved the unaudited financial results for the quarter ended June 30, 2026. The company also received a Limited Review Report from its independent auditor, DM KH & Co. The results, prepared in accordance with Ind AS 34, were found to be free of material misstatements. The board meeting commenced at 4:00 PM and concluded at 6:00 PM. Further details will be available on the company's website.

Brooks Laboratories Ltd announced that its Board of Directors met on August 13, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026. The company has submitted these results along with a limited review report from its independent auditor, DM KH & Co. The financial statements were prepared in accordance with Indian Accounting Standard 34 (Ind AS 34) and other recognized accounting principles. The auditor's report states that based on their review, nothing came to their attention to suggest material misstatements in the accompanying unaudited standalone financial results. The meeting commenced at 4:00 PM and concluded at 6:00 PM. The information will also be available on the company's website.

Brooks Laboratories Ltd has announced its 24th Annual General Meeting (AGM) scheduled for September 3, 2026, to be held via Video Conferencing. The company is dispatching a letter to shareholders, particularly those without registered email addresses, providing a weblink to the complete Annual Report for the Financial Year 2025-26. This communication also serves as a reminder for shareholders holding physical securities to update their KYC details as per SEBI regulations, including PAN, address, mobile number, bank account, and specimen signature, to ensure continued eligibility for payments like dividends. The RTA, MUFG Intime India Private Limited, is facilitating these updates.

Brooks Laboratories Ltd has announced its 24th Annual General Meeting (AGM) will be held on September 3, 2026, at 9:00 AM IST through Video Conferencing/Other Audio-Visual Means. The meeting will cover ordinary business such as adopting the audited standalone and consolidated financial statements for FY2025-26 and reappointing a director retiring by rotation. Special business includes ratifying the remuneration of Cost Auditors M/s. Balwinder & Associates for FY2026-27, approving related party transactions, and approving remuneration for senior management, Mr. Atul Ranchal (President - Strategy) up to ₹15,00,000 per month and Mr. Rajesh Mahajan (President - Procurement) up to ₹8,00,000 per month.

Brooks Laboratories Ltd has announced that its Board of Directors will convene on August 13, 2026. The primary agenda item is to consider and approve the unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026, along with the Limited Review Report from the statutory auditors. Additionally, the company confirmed the closure of the trading window for directors and designated persons from July 1, 2026, which will reopen 48 hours after the financial results are declared.

Brooks Laboratories Ltd has announced the appointment of Mr. Rajesh Mahajan as President - Trading and Senior Management Personnel, effective July 17, 2026. Mr. Mahajan brings over 20 years of experience in the pharmaceutical industry, with a strong background in formulations and manufacturing operations. His expertise includes driving growth in the formulation business and leading new project planning and business development initiatives. This appointment is in line with Listing Regulations and SEBI Master Circulars.

Brooks Laboratories Ltd has entered into a binding Memorandum of Understanding (MoU) with Steriscience Specialties Private Limited and Brooks Steriscience Limited (BSL). This follows a prior disclosure regarding the proposed sale of a portion of its shareholding in BSL. The MoU outlines the commercial understanding for Brooks Laboratories' continuing investment in BSL post-transaction. Key terms include value protection for the retained investment, anti-dilution rights, principles for capital requirements, and interim rights. The transaction is expected to reduce Brooks Laboratories' stake in BSL from 49% to 32.67% and generate an immediate cash inflow of approximately ₹106.33 crores for growth and expansion.

Brooks Laboratories Limited has announced the incorporation of its wholly owned subsidiary, Abridge Speciality Limited, on July 2, 2026. The new entity, with an authorized share capital of ₹1,00,000, will operate in the manufacturing and marketing of pharmaceuticals and related products. This move aligns with the company's strategic objective to expand its business. Abridge Speciality Limited is a related party to Brooks Laboratories Limited, which will hold 100% of its share capital. The subsidiary is yet to commence business operations, hence turnover and net worth are not applicable.

Brooks Laboratories Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This restriction will be in effect from July 1, 2026, until 48 hours after the declaration of the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026. The closure aligns with SEBI (Prohibition of Insider Trading) Regulations and the company's internal code of conduct, aimed at preventing insider trading during the period leading up to and immediately following the financial results announcement.

Brooks Laboratories Ltd announced the approval by its Board of Directors for the sale of 51,220 equity shares, representing 16.33% of its holding, in its subsidiary Brooks Steriscience Limited to Steriscience Specialties Private Limited. The transaction, valued at ₹20,760 per share, aggregates to approximately ₹106.33 crore. This partial divestment is part of the company's strategy to monetize its investment and will be used for growth initiatives, including expansion and general corporate purposes. Post-transaction, Brooks Laboratories will retain a 32.67% stake in Brooks Steriscience Limited.